Skip to content

Comparision of the effect of subconjunctival injection of Bevacizumab and Mitomycin in outcome of Ahmed Glaucoma Valve (AGV)

Comparision of the effect of subconjunctival injection of Bevacizumab and Mitomycin in outcome of Ahmed Glaucoma Valve (AGV) implantation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210521051355N1
Enrollment
54
Registered
2021-09-28
Start date
2021-09-08
Completion date
Unknown
Last updated
2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uncontrolled glaucoma. Glaucoma secondary to other eye disorders, unspecified eye, severe stage

Interventions

Intervention 1: To insert the Ahmed Glaucoma Valve (AGV),peritomy will performed by conjunctival incision at 4 mm from the limbus in the superotemporal quadrant. Ahmed valve will prime with balance

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Uncontrolled glaucoma with full medications First shunt candidate patients

Exclusion criteria

Exclusion criteria: Under 18 years old patients Secondary neovascular glaucoma due to tumor or uveitis Under 6 month follow up Previous shunts pregnancy

Design outcomes

Primary

MeasureTime frame
IOP changes after Ahmed valve implantation with sub-conjunctival injection of bevacizumab or mitomycin. Timepoint: IOP measurement before surgery, 1, 7, 30 days and 3, at least 6 month after surgery and in the last follow up after surgery. Method of measurement: Goldman tonometer.

Secondary

MeasureTime frame
Number of glaucoma medication after surgery. Timepoint: Baseline,first day,one week,first month,three months,6 months and last follow up. Method of measurement: counting the number of antiglaucoma drugs.;Complications in each group. Timepoint: first day,First week,first month,three months,6months after surgery. Method of measurement: qualitative and descriptive.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Arezoo Miraftabi

Iran University of Medical Sciences

Kian2_gh@yahoo.com+98 21 6435 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026